Ryvu Therapeutics SA (RVU) — Capital Reinvestment Ratio
Latest as of December 2022:
0.07x
Ryvu Therapeutics SA (RVU) has a Capital Reinvestment Ratio of 0.07x as of December 2022, meaning it reinvests 0% of its operating cash flow (zł59.92 Million) in capital expenditures (zł4.22 Million). See RVU FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.07x
Capex / Operating Cash Flow
Operating Cash Flow
zł59.92 Million
PLN
Capital Expenditures
zł4.22 Million
PLN
Data as of
Dec 2022
Most recent filing
Ryvu Therapeutics SA Capital Reinvestment Ratio (2017–2022)
This chart tracks Ryvu Therapeutics SA's Capital Reinvestment Ratio across 2 annual periods.
Annual Capital Reinvestment Ratio for Ryvu Therapeutics SA (2017–2022)
Year-by-year Capital Reinvestment Ratio for Ryvu Therapeutics SA from 2017 to 2022. For live market cap and broader valuation context, see Ryvu Therapeutics SA market cap and net worth.
| Year | Reinvestment Ratio | Operating CF (PLN) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2022 | 0.44x | zł21.32 Million | zł9.29 Million | ▼ -77.8% |
| 2017 | 1.96x | zł10.98 Million | zł21.56 Million | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow